Sat.Mar 23, 2024 - Fri.Mar 29, 2024

article thumbnail

GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable

STAT

Diabetes drugs are too expensive in the U.S., and insulin is infamously six to 13 times more expensive here than in comparable high-income countries. And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition. The study, led by Melissa Barber, a Yale postdoctoral fellow, and conducted in collaboration with Doctors Without Borders, a nonprofit medical organization working

Diabetes 362
article thumbnail

Who’s getting left behind in the weight loss bonanza?

PharmaVoice

As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.

278
278
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

An open letter: Concerns on electoral bonds and pharma industry

Express Pharma

Chandru Chawla, a pharma veteran writes an open letter to those CEOs of Pharmaceutical companies who have NOT purchased Electoral Bonds and have NOT made political donations through other means Dear Pharma CEO who did NOT make political donations Compliments from an ordinary soon-to-be senior citizen and a consumer of medicines. Recently, ordinary folks like me have been bombarded with this alleged scam being referred to as Chanda Do Dhanda Lo.

article thumbnail

Nanoscope preps filing for retinitis pigmentosa gene therapy

pharmaphorum

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of underlying genetic mutations.

128
128
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Why researchers think human milk could repair the gut microbiome and reduce infections

STAT

For babies who are breastfed, their first source of sustenance is filled with proteins, sugars, hormones, vitamins, and minerals — just the right amount of nutrients for an infant. That milk could also lower the risk of asthma , diabetes, and allergies. And it could make low-birth-weight, preterm babies up to 10 times less likely to develop necrotizing enterocolitis , a common intestinal disorder.

Diabetes 361
article thumbnail

Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim

PharmaVoice

Deborah Reardon is leading a new pillar that asks, ‘Are we looking at this from a patient lens and not from a Boehringer lens?

243
243

More Trending

article thumbnail

Brainomix AI shows its worth in AZ pulmonary fibrosis trial

pharmaphorum

Brainomix's e-Lung AI can accurately identify idiopathic pulmonary fibrosis patients most likely to progress and could inform the clinical trial design for new therapies

119
119
article thumbnail

Covid’s scientific silver lining: A chance to watch the human immune system respond in real time

STAT

While an increasingly anxious world watched a new coronavirus spread across the globe in early 2020, veteran immunologist Rafi Ahmed quickly grasped that his field was about to experience something truly extraordinary. His former student Ali Ellebedy was gnawed by frustration as Covid shutdowns stalled his influenza research; it took until the summer, when mass vaccination planning hit his radar, before the same realization kicked in.

Immunity 364
article thumbnail

To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach

PharmaVoice

Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.

Diabetes 162
article thumbnail

FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

BioPharma Dive

The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.

114
114
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Building the patient experience into observational studies produces stronger real-world evidence

pharmaphorum

Incorporating the patient experience into observational studies can enhance the quality of real-world evidence gathered. Learn how patient-centred approaches can lead to stronger research outcomes.

119
119
article thumbnail

STAT+: Why the world’s most expensive drug might not be all that overpriced

STAT

The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge a few times a year to scold drugmakers for pricing their latest cancer or MS advance far beyond reason. But last year, its staff sat down and concluded a forthcoming treatment was worth up to $3.9 million — more than any medicine in history, more than a 45-year supply of Humira, the autoimmune drug often held up as an emblem of America’

article thumbnail

Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS

PharmaVoice

Ahead of more guidance from the FDA on diversity in clinical trials, Takeda is aiming to beat industry standards.

147
147
article thumbnail

Bristol Myers says KRAS drug succeeds in key trial

BioPharma Dive

Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.

117
117
article thumbnail

Aduhelm and an expensive failure to launch

pharmaphorum

Aduhelm (aducanumab) and Leqembi are examples of controversial drugs that faced challenges with FDA approval. Learn more about the expensive failure to launch of these medications.

114
114
article thumbnail

STAT+: Steward Health Care has deal to sell doctor network to UnitedHealth

STAT

Troubled hospital operator Steward Health Care, grappling with a financial crisis that’s engulfed its eight Massachusetts hospitals, has moved to shore up its finances by striking a deal to sell its nationwide physician network to insurance giant UnitedHealth’s Optum Care unit. The proposed sale of the doctors group, called Stewardship Health, is part of Steward’s plan to bolster its national system of 33 hospitals after the Dallas-based company last year fell behind in payi

Hospitals 363
article thumbnail

Veeda Clinical Research acquires Heads, a European CRO

Express Pharma

Veeda Clinical Research has acquired Heads, a privately held European CRO, which specialises in conducting clinical trials in oncology. Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region. Veeda expands its reach to major geographies and adds capabilities of late-sta. ge clinical trial execution with strong focus on oncology with this acqusition The acquisition provides Heads a strong operationa

111
111
article thumbnail

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

Pharmafile

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). This approval follows positive results from the phase 3 CHAMPION-NMOSD trial, which were published in […] The post FDA approves AstraZeneca’s Ultomiris for NMOSD treatment appeared fir

111
111
article thumbnail

Female leadership and lessening disease burden

pharmaphorum

As Women’s History Month comes to its final week, today’s podcast sees web editor Nicole Raleigh in conversation with Debra Weiss, COO of the Bill & Melinda Gates Medical Research Institute (Gates MRI), discussing her role as a female leader in the leader and the non-profit organisation’s work in developing novel biomedical interventions and lessening the burden of disease in LMICs.

116
116
article thumbnail

STAT+: Some nonprofit hospitals spend less on charity care than they receive in tax breaks, new analysis shows

STAT

A new study of hospitals’ charity care spending suggests nonprofit hospitals really aren’t that different from their for-profit counterparts. One major benefit of being a nonprofit hospital is receiving tax exemptions on property taxes, income taxes, and sales taxes. Experts told STAT that implies a “social contract” with taxpayers, where these hospitals will help take care of the most vulnerable.

Hospitals 362
article thumbnail

AstraZeneca India gets dual CDSCO approval for Trastuzumab deruxtecan

Express Pharma

AstraZeneca Pharma India has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilised powder for concentrate for solution for infusion 100mg from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India for two additional indications. The new indications are: HER2-low metastatic breast cancer : Trastuzumab deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic

article thumbnail

Pharmacy First: Tips for diagnosing and treating uncomplicated UTI in women

The Pharmacist

CLINICAL UPDATE How are you getting on with Pharmacy First? GP Dr Toni Hazell presents useful tips for diagnosing and treating uncomplicated UTI in women Most community pharmacies in England are now running the Pharmacy First service which enables them to diagnose and treat seven specific conditions. Under the service, pharmacists can prescribe set medications […] The post Pharmacy First: Tips for diagnosing and treating uncomplicated UTI in women appeared first on The Pharmacist.

article thumbnail

Highlighting the disruptors: Innovation for now and tomorrow at WIRED Health 2024, Part One

pharmaphorum

Explore the cutting-edge innovations featured at WIRED Health 2024, including insights on Alphafold, clean air technology, and Lingo. Stay informed about the latest disruptors shaping the future.

104
104
article thumbnail

STAT+: Payments by drug and device makers to doctors remain widespread, but also vary considerably

STAT

The financial ties between drug and device makers and some physicians remains pervasive, despite concerns such relationships may influence medical practice, according to a new analysis of payments made over a recent 10-year span. From 2013 to 2022, pharmaceutical and device companies made more than 85 million payments totaling $12.1 billion to approximately 826,300 physicians.

353
353
article thumbnail

Novo Nordisk to acquire Cardior Pharmaceuticals to strengthen pipeline in cardiovascular disease

Express Pharma

The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure Novo Nordisk and Cardior Pharmaceuticals has announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.

article thumbnail

Pharmacy technicians to supply medicines under PGDs

The Pharmacist

Pharmacy technicians will be enabled to supply medicines under patient group directions (PGDs), subject to parliamentary approval, the government has announced today. As a result, they may be able to provide Pharmacy First consultations or administer vaccinations, the Department of Health and Social Care (DHSC) has said. This follows a public consultation, which the government […] The post Pharmacy technicians to supply medicines under PGDs appeared first on The Pharmacist.

article thumbnail

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

pharmaphorum

Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.1 billion, adding expertise in RNA therapeutics and a heart failure therapy in mid-stage trials.

122
122
article thumbnail

Does decaf coffee contain a harmful additive? Advocates want to ban a certain chemical in the brew

STAT

WASHINGTON — There’s a fight brewing over the future of decaf coffee. Consumer health advocates are petitioning the Food and Drug Administration to ban a key chemical, methylene chloride, used to decaffeinate coffee beans. While the chemical is almost entirely removed during the decaffeination process, advocates say that a little-known nearly 66-year-old federal law mandates the agency ban the additive because it has been proven to cause cancer in rodents.

351
351
article thumbnail

The Rising Tide of Biopharma Manufacturing Costs

Pharmaceutical Commerce

In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses the specific factors contributing to rising manufacturing costs.

104
104
article thumbnail

FDA approves Merck lung disease drug acquired in $11B deal

BioPharma Dive

Merck is couting on Winrevair, which it acquired by buying Acceleron Pharma, to help soften the blow when Keytruda loses patent protection later this decade.

114
114
article thumbnail

Japan clears first CLDN18.2 drug, Astellas’ Vyloy

pharmaphorum

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment for stomach cancer. The Ministry of Health, Labour and Welfare (MHLW) has cleared Vyloy (zolbetuximab) for use in combination with chemotherapy for patients with HER2-negative CLDN18.2-positive advanced or recurrent gastric cancer that cannot be treated with surgery.

article thumbnail

Disparities in donor acceptance rates point to need for more equitable heart transplant care

STAT

When a patient is going through end-stage heart failure, the best treatment is to get a heart transplant. The basic steps are familiar: First a patient gets on the waiting list, and then the wait begins for the offers. In recent years, access to donor hearts has gone up thanks to a change in heart allocation policy, but there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, according to new research published Monday in the Journal of

363
363
article thumbnail

Sanofi signs distribution pact with Cipla for CNS portfolio in India

Express Pharma

Sanofi India and Cipla announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category. While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla w

105
105
article thumbnail

Viking stays in obesity drug race with early data for weight loss pill

BioPharma Dive

The results are from a small Phase 1 study, but suggest Viking’s oral GLP-1 drug may not come with high rates of gastrointestinal side effects.

116
116
article thumbnail

Dissatisfaction with NHS ‘at record high’

pharmaphorum

More than half (52%) of people who participated in a major survey of the GB public were dissatisfied with the NHS, as staff shortages, strikes, and record waiting lists take their toll. The results from the annual British Social Attitudes (BSA) survey came from 3,000 people interviewed across England, Scotland, and Wales and showed that less than a quarter (24%) were satisfied with the health service, a 29 percentage drop in three years.

107
107